Expression Therapeutics, a fully integrated clinical stage biotechnology company developing novel cell and gene therapies, opened its state-of-the-art 43,000 square foot cell and viral vector manufacturing facility in Cincinnati, OH.
 
The company’s manufacturing subsidiary, Expression Manufacturing LLC, provides end-to-end research and development capabilities and early phase and commercial scale manufacturing of both GMP cell and viral vector products. The facility manufactures lentiviral (LV) and adeno associated viral (AAV) vectors.
 
“With GMP vector manufacturing backlogs typically exceeding 18 months, we wanted to bring in-house manufacturing capabilities online and provide CDMO services to commercial clients as soon as possible,” said Bill Swaney, president, Expression Manufacturing LLC. “The opening of the facility allows us to immediately support our internal therapeutic pipeline in hematology and oncology. In fact, we just completed three full-scale engineering runs for our lead cell therapy product ET206, which is intended to treat Neuroblastoma.”
 
Mr. Swaney is an internationally recognized expert in cell and gene therapy manufacturing and has conducted over 70 GMP production runs for academic and commercial clients. He comes to Expression Manufacturing from the Cincinnati Children’s Hospital Medical Center where he was the director of the vector production facility and viral vector core.
 
Mohan Rao, CEO, Expression Therapeutics, Inc., said, “The opening of our manufacturing facility signals our commitment to strengthen southwest Ohio’s position as an emerging location for biotechnology while also rapidly advancing our internal therapeutic pipeline through clinical trials and commercialization.”